Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Common Equity: 2019-2024

Historic Common Equity for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $216.0 million.

  • C4 Therapeutics' Common Equity fell 36.37% to $154.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.4 million, marking a year-over-year decrease of 36.37%. This contributed to the annual value of $216.0 million for FY2024, which is 12.24% down from last year.
  • As of FY2024, C4 Therapeutics' Common Equity stood at $216.0 million, which was down 12.24% from $246.1 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Common Equity ranged from a high of $389.6 million in FY2021 and a low of $216.0 million during FY2024.
  • In the last 3 years, C4 Therapeutics' Common Equity had a median value of $246.1 million in 2023 and averaged $250.4 million.
  • Its Common Equity has fluctuated over the past 5 years, first spiked by 350.79% in 2020, then dropped by 25.76% in 2022.
  • Yearly analysis of 5 years shows C4 Therapeutics' Common Equity stood at $280.8 million in 2020, then surged by 38.75% to $389.6 million in 2021, then decreased by 25.76% to $289.2 million in 2022, then dropped by 14.91% to $246.1 million in 2023, then declined by 12.24% to $216.0 million in 2024.